For instance, in the phase III SOLAR-1 trial, which evaluated alpelisib plus fulvestrant versus fulvestrant in PIK3CA-mutated, hormone-receptor-positive advanced breast cancer, PIK3CA mutations detected in plasma were probably correlated with greater disease burden and better response to the combination of alpelisib and fulvestrant [11]. Here, PIK3CA is linked to breast cancer.